伏立康唑属新一代三唑类抗真菌药,2002年美国FDA批准上市,目前也已在国内上市。伏立康唑的体内代谢呈非线性药动学特性,即给药剂量增加时,药时曲线下面积(AUC)急剧增加。伏立康唑主要在肝脏通过细胞色素P450 (CYP450)的同工酶CYP2C19进行代谢,其代谢有弱代谢和 Voriconazole is a new generation of triazole antifungal drugs, the FDA approved the listing in 2002, is also currently in the domestic market. The in vivo metabolism of voriconazole showed a non-linear pharmacokinetic profile, that is, when the dose was increased, the area under the curve (AUC) sharply increased. Voriconazole is mainly metabolized in the liver by the CYP2C19 isoenzyme of cytochrome P450 (CYP450), whose metabolism is weakly metabolized and